Intervest Offices & Warehouses NV: Press release – Persbericht – Communiqué de presse: results of Simplified Squeeze-Out Acceptance Period of TPG on Intervest
Dear Madam, Sir,
Please find hereunder the links to Intervest Offices & Warehouses’ latest press release regarding the results of Simplified Squeeze-Out Acceptance Period of TPG on Intervest.
Geachte mevrouw, meneer,
Gelieve hierbij de links te vinden naar het recente persbericht van Intervest Offices & Warehouses betreffende de resultaten aan van de Aanvaardingsperiode van het vereenvoudigd uitkoopbod van TPG op Intervest.
Chère Madame, Cher Monsieur,
Veuillez trouver ci-dessous les liens vers le récent communiqué de presse d’Intervest Offices & Warehouses concernant les résultats de la période d'acceptation de l’offre de reprise simplifiée de TPG sur Intervest.
Attachments
- EN_Intervest results squeezeout_fin
- NL_Intervest results squeezeout_fin
- FR_Intervest results squeezeout_fin
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
QuTEM Receives GMP Certificates and Manufacturing Permits for Transmission Electron Microscopy Laboratory from the Swedish Medical Products Agency17.5.2024 08:00:00 CEST | Press release
STOCKHOLM, Sweden, May 17, 2024 (GLOBE NEWSWIRE) -- QuTEM AB (formerly Vironova BioAnalytics AB), a leading provider of transmission electron microscopy (TEM) services, proudly announces the receipt of GMP (Good Manufacturing Practice) Certificates and Manufacturing Permits for Independent Quality Control Laboratories issued by the Swedish Medical Products Agency (Läkemedelsverket). QuTEM is thereby authorized to perform critical quality control analysis essential for the release of medicines to the market. The GMP Certificates and Manufacturing Permits cover medicinal and investigational medicinal products for both human and veterinary use. GMP regulations are formal standards established by regulatory bodies worldwide to ensure the quality, safety, and efficacy of pharmaceutical products. Manufacturing Permits for Independent Quality Control Laboratories are granted by the Swedish regulatory authority since January 2024 to laboratories that conduct tests directly impacting the releas
Teckningskurs för nyttjande av teckningsoptioner av serie TO7 i Terranet AB har fastställts till 0,073 SEK per aktie av serie B. Teckningsperioden inleds på måndag, den 20 maj 2024.17.5.2024 08:00:00 CEST | Pressemelding
Terranet AB (publ) (”Terranet” eller ”Bolaget”) emitterade 182 664 660 teckningsoptioner av serie TO7 i samband med Bolagets företrädesemission under det andra kvartalet 2023. Varje teckningsoption ger rätt att teckna en (1) ny B-aktie i Bolaget. Teckningskursen för teckningsoptionerna av serie TO7 ska fastställas till 70 procent av den volymvägda genomsnittskursen i Bolagets aktie på Nasdaq First North Premier Growth Market under mätperioden från och med den 2 maj 2024 till och med den 16 maj 2024, dock inte lägre än kvotvärdet för Bolagets aktier och inte högre än 0,27 SEK per aktie. Den volymvägda genomsnittskursen i Bolagets aktie uppgick under mätperioden till 0,104 SEK och således har teckningskursen fastställts till 0,073 SEK. Investerat belopp avrundas uppåt till två decimaler. Teckning av aktier med stöd av teckningsoptioner av serie TO7 pågår från och med den 20 maj 2024 till och med den 3 juni 2024. Fullständiga villkor för teckningsoptionerna finns att tillgå på Bolagets we
The subscription price for exercise of warrants of series TO7 in Terranet AB has been set to SEK 0.073 per share of series B. The exercise period begins on Monday, May 20, 2024.17.5.2024 08:00:00 CEST | Press release
Terranet AB (publ) (” Terranet” or the” Company”) issued 182 664 660 warrants of series TO7 in connection with the Company’s rights issue in the second quarter of 2023. Each warrant gives the right to subscribe for one (1) new share of series B in the Company. The subscription price for the warrants of series TO7 shall correspond to 70 percent of the volume weighted average price of the Company´s share on Nasdaq First North Premier Growth Market during the measurement period from and including the May 2, 2024, up until and including the May 16, 2024. However, not lower than the nominal value of the Company's share, and not higher than SEK 0.27 per share. The volume-weighted average price of the Company's share of series B during the measurement period amounted to approximately SEK 0.104. Thus, the subscription price has been determined to SEK 0.073. The invested amount must be rounded up to two decimals. The exercise period for warrants of series TO7 runs from May 20, 2024, up until an
First quarter 2024 results: SCOR starts 2024 with a strong first three-months net income of EUR 196 million17.5.2024 07:30:54 CEST | Press release
Press release 17 May 2024 - N° 07 First quarter 2024 results SCOR starts 2024 with a strong first three-months net income of EUR 196 million Group net income of EUR 196 million in Q1 2024 (EUR 176 million adjusted1) Group Economic Value2 under IFRS 17 of EUR 9.6 billion as of 31 March 2024, up +4.8%3 (+4.1% at constant economics3,4) compared with 31 December 2023, implying an Economic Value per share of EUR 54 (vs. EUR 51 as of 31 December 2023) Estimated Group solvency ratio of 215%5 as of 31 March 2024Annualized Return on Equity of 17.3% (15.5% adjusted1) in Q1 2024 Insurance revenue of EUR 4,113 million in Q1 2024 (+6.0%6 compared to Q1 2023)P&C combined ratio of 87.1% in Q1 2024 (+1.9pts compared to Q1 2023)L&H insurance service result7 of EUR 72 million in Q1 2024 (EUR -200 million compared to Q1 2023) Investments regular income yield of 3.5% in Q1 2024 (+0.7pts compared to Q1 2023) SCOR SE’s Board of Directors met on 16 May 2024, under the chairmanship of Fabrice Brégier, to appr
Constellation Brands to Present at the Bernstein 40th Annual Strategic Decisions Conference on Wednesday, May 29, 202416.5.2024 22:30:20 CEST | Press release
VICTOR, N.Y., May 16, 2024 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE: STZ), a leading beverage alcohol company, announced today that Bill Newlands, President and Chief Executive Officer, and Garth Hankinson, Executive Vice President and Chief Financial Officer, will participate in a fireside chat at the Bernstein 40th Annual Strategic Decisions Conference on Wednesday, May 29, 2024 in New York, NY. The presentation is scheduled to begin at 2:30 p.m. EDT and is expected to cover the company’s strategic business initiatives, financial metrics, and operating performance, as well as outlook for the future. A live, listen-only webcast of the presentation will be available on the company’s investor relations website at ir.cbrands.com under the News & Events section. When the presentation begins, financial information discussed in the presentation, and a reconciliation of reported GAAP financial measures with comparable and other non-GAAP financial measures, will also be available